Abstract
Abstract The tumor microenvironment has a critical role in cancer progression. We have identified LIF as a regulator of the tumor stroma, specifically of the tumor immune response. LIF is a cytokine with a crucial role in embryogenesis and previous work has identified LIF as an oncogenic factor that regulates cancer-initiating cells, cancer-associated fibroblasts and chemo- and radioresistance. We have observed that in tumors expressing high levels of LIF, the blockade of LIF inhibited tumor growth and caused tumor regression through the engagement of an immune response. The anti-tumor effect of LIF neutralization was mediated by the tumor-associated macrophages through the regulation of a set of cytokines that impacted on the T cell response. The LIF-mediated immune suppression was observed in several tumor types with an important incidence in glioblastoma. Our results identify LIF as a critical cytokine in the immune response to cancer and a promising therapeutic target. Citation Format: Joan Seoane. LIF in cancer [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr CN08-03. doi:10.1158/1535-7163.TARG-19-CN08-03
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
